Quick Answer
Coherus Oncology, Inc. reported Research And Development Expense of $108.89 million for the year ending 2025.
- Coherus Oncology, Inc. showed an increase of +18.6% in Research And Development Expense from 2024 to 2025.
- This data is from Coherus Oncology, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2013: $4.93 million | Q1 2014: $13.94 million | Q2 2014: $18.93 million | Q3 2014: $18.50 million | Q1 2015: $36.47 million | Q2 2015: $56.94 million | Q3 2015: $68.22 million | Q1 2016: $65.31 million | Q2 2016: $65.54 million | Q3 2016: $64.57 million | Q1 2017: $53.78 million | Q2 2017: $34.50 million | Q3 2017: $42.63 million | Q1 2018: $25.46 million | Q2 2018: $26.52 million | Q3 2018: $31.60 million | Q1 2019: $18.79 million | Q2 2019: $18.88 million | Q3 2019: $21.57 million | Q1 2020: $33.11 million | Q2 2020: $26.17 million | Q3 2020: $38.85 million | Q1 2021: $203.49 million | Q2 2021: $54.77 million | Q3 2021: $54.09 million | Q1 2022: $82.92 million | Q2 2022: $41.61 million | Q3 2022: $45.81 million | Q1 2023: $34.15 million | Q2 2023: $23.27 million | Q3 2023: $25.65 million | Q1 2024: $28.42 million | Q2 2024: $20.60 million | Q3 2024: $22.05 million | Q1 2025: $24.36 million | Q2 2025: $26.31 million | Q3 2025: $27.25 million.
- Over the full 14 years of available data (2012 to 2025), Coherus Oncology, Inc.'s Research And Development Expense has grown by 212.1%.
- Historical annual values: Fiscal year 2025: $108.89 million | Fiscal year 2024: $91.83 million | Fiscal year 2023: $109.44 million | Fiscal year 2022: $199.36 million | Fiscal year 2021: $363.11 million | Fiscal year 2020: $142.76 million | Fiscal year 2019: $94.19 million | Fiscal year 2018: $110.24 million | Fiscal year 2017: $162.39 million | Fiscal year 2016: $254.44 million | Fiscal year 2015: $213.06 million | Fiscal year 2014: $78.22 million | Fiscal year 2013: $31.28 million | Fiscal year 2012: $34.89 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: